These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 20233535)

  • 1. Valsartan increases circulating adiponectin levels without changing HOMA-IR in patients with type 2 diabetes mellitus and hypertension.
    Lee JM; Kim JH; Son HS; Hong EG; Yu JM; Han KA; Min KW; Chang SA
    J Int Med Res; 2010; 38(1):234-41. PubMed ID: 20233535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of valsartan on insulin sensitivity in patients with primary hypertension.
    Top C; Cingözbay BY; Terekeci H; Küçükardali Y; Onde ME; Danaci M
    J Int Med Res; 2002; 30(1):15-20. PubMed ID: 11921494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.
    Yilmaz MI; Sonmez A; Caglar K; Celik T; Yenicesu M; Eyileten T; Acikel C; Oguz Y; Yavuz I; Vural A
    Nephrology (Carlton); 2007 Apr; 12(2):147-53. PubMed ID: 17371337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension.
    Saiki A; Ohira M; Endo K; Koide N; Oyama T; Murano T; Miyashita Y; Shirai K
    Diabetes Res Clin Pract; 2006 Dec; 74(3):242-8. PubMed ID: 16713009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
    Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
    Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations of insulin resistance and the serum adiponectin level in patients with type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment.
    Fuke Y; Fujita T; Satomura A; Wada Y; Matsumoto K
    Diabetes Technol Ther; 2010 May; 12(5):393-8. PubMed ID: 20388049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus.
    Nomura S; Shouzu A; Omoto S; Nishikawa M; Fukuhara S; Iwasaka T
    Thromb Res; 2006; 117(4):385-92. PubMed ID: 15896827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice.
    Shiuchi T; Iwai M; Li HS; Wu L; Min LJ; Li JM; Okumura M; Cui TX; Horiuchi M
    Hypertension; 2004 May; 43(5):1003-10. PubMed ID: 15037562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
    Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome.
    Ichikawa Y
    Intern Med; 2007; 46(17):1331-6. PubMed ID: 17827829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice.
    Cole BK; Keller SR; Wu R; Carter JD; Nadler JL; Nunemaker CS
    Hypertension; 2010 Mar; 55(3):715-21. PubMed ID: 20100990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension.
    Hanefeld M; Abletshauser C
    J Int Med Res; 2001; 29(4):270-9. PubMed ID: 11675899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
    Guo LL; Pan Y; Jin HM
    Nephrol Dial Transplant; 2009 Jun; 24(6):1876-83. PubMed ID: 19164322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension.
    Okura T; Watanabe S; Kurata M; Koresawa M; Irita J; Enomoto D; Jotoku M; Miyoshi K; Fukuoka T; Higaki J
    Clin Exp Hypertens; 2008 Jul; 30(5):415-22. PubMed ID: 18633763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
    Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
    Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of valsartan on lipid profile in normotensive type 2 diabetic patients.
    Velija-Asimi Z; Heljić B
    Med Arh; 2005; 59(5):311-2. PubMed ID: 16134756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice.
    Ushijima K; Takuma M; Ando H; Ishikawa-Kobayashi E; Nozawa M; Maekawa T; Shiga T; Fujimura A
    Eur J Pharmacol; 2013 Jan; 698(1-3):505-10. PubMed ID: 23195328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in plasma lipids during renin-angiotensin system blockade by combination therapy (enalapril plus valsartan) in patients with diabetes and hypertension.
    Gaudio G; Guasti L; Schizzarotto A; Simoni C; Crespi C; Cimpanelli M; Klersy C; Grandi AM; Riganti G; Venco A
    J Cardiovasc Pharmacol; 2005 Apr; 45(4):362-6. PubMed ID: 15772526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.